Clinical trial
Study of DOXIL/CAELYX (Pegylated Liposomal Doxorubicin) and VELCADE (Bortezomib)…
NCT00103506 · Janssen Research & Development, LLC, Industry · Completed
Key facts
| NCT number | NCT00103506 |
|---|---|
| Title | Study of DOXIL/CAELYX (Pegylated Liposomal Doxorubicin) and VELCADE (Bortezomib) or VELCADE Monotherapy for the Treatment of Relapsed Multiple Myeloma |
| Official title | A Randomized Controlled Study of DOXIL/CAELYX (Doxorubicin HCL Liposome Injection) and VELCADE (Bortezomib) or VELCADE Monotherapy for the Treatment of Relapsed Multiple Myeloma |
| Lead sponsor | Janssen Research & Development, LLC, Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Multiple Myeloma |
| Intervention type | Drug |
| Interventions | Bortezomib (VELCADE), Doxorubicin hydrochloride (DOXIL/CAELYX) |
| Enrollment | 646 |
| Start date | Dec 1, 2004 |
| Primary completion | May 1, 2014 |
| Completion | Jun 1, 2014 |
| First posted | Feb 10, 2005 |
| Last update posted | Oct 19, 2015 |
| Countries | Argentina, Australia, Austria, Belgium, Canada, Czechia, France, Israel, Netherlands, Poland, Portugal, Russia and 5 more |
At a glance
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: